Invention Grant
- Patent Title: Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-YL]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof
-
Application No.: US15861586Application Date: 2018-01-03
-
Publication No.: US10370332B2Publication Date: 2019-08-06
- Inventor: Stéphane Pintat , Stephen John Davies , David Festus Charles Moffat
- Applicant: Macrophage Pharma Limited
- Applicant Address: GB Windsor, Berkshire
- Assignee: Macrophage Pharma Limited
- Current Assignee: Macrophage Pharma Limited
- Current Assignee Address: GB Windsor, Berkshire
- Agency: Norton Rose Fulbright US LLP
- Priority: GB1218640.9 20121017; GB1306881.2 20130416
- Main IPC: C07D213/73
- IPC: C07D213/73
![Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-YL]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof](/abs-image/US/2019/08/06/US10370332B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides a compound which is: tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate or a salt, hydrate or solvate thereof. The present invention also provides a pharmaceutical composition comprising the compound together with one or more pharmaceutically acceptable carriers and/or excipients. The compound and composition are useful for inhibiting the activity of a p38 MAP kinase enzyme. As such they may be used in the treatment of a autoimmune or inflammatory disease, or a cell proliferative disease. In addition, the invention provides an acid produced by hydrolysis of the ester group of the compound of the invention. The acid is N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine.
Public/Granted literature
Information query
IPC分类: